PDL BioPharma, Roche deal

PDLI said ROCZ will discontinue its involvement in the development of daclizumab for transplant

Read the full 145 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE